We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rare Breast Cancer Treated with Radiation May Lower Recurrence Rate

By HospiMedica International staff writers
Posted on 13 Aug 2008
Patients with a rare type of breast cancer may benefit from radiation therapy in addition to surgery to prevent recurrence, according to recent research.

Phyllodes tumors are rare tumors that develop in the connective tissue of the breast, in contrast to more common carcinomas, which develop in the ducts or lobules of the breast. More...
Most patients are treated for phyllodes tumors with either a lumpectomy or mastectomy, with only a small portion of patients receiving radiation therapy. Traditionally, adjuvant radiation therapy is recommended for cancer patients with local recurrence risks of 15% or greater, but the benefit of adjuvant radiation therapy has not been extensively studied for phyllodes tumors because they are so rare.

Researchers from the division of radiation oncology, department of medical physics, and department of general and oncologic surgery at City of Hope [U.S.] National Medical Center (Duarte, CA, USA) tried to determine the local recurrence rates of phyllodes tumors based on tumor size and the type of surgery performed, and whether adjuvant radiation therapy should be considered as a treatment for some phyllodes tumor patients to reduce their local recurrence rate.

"Typically, these tumors are treated well by surgery alone. However, local recurrences are not uncommon,” commented Richard Pezner, M.D., lead author of the study and a radiation oncologist at City of Hope National Medical Center. The study's findings were reported in the July 2008, issue of the International Journal of Radiation Oncology • Biology • Physics.

The study investigators reviewed records of 478 patients with malignant phyllodes tumors who were treated between March 1964 and August 2005. The records came from the IMPAC U.S. National Oncology Database, which consists of tumor registries from 130 hospitals.

The researchers found that the risk of local recurrence for phyllodes tumors was related to tumor size and the type of surgery received. They determined that adjuvant radiation therapy should be evaluated for phyllodes tumor patients who received lumpectomies for tumors at least 2 cm in size or a mastectomy for tumors at least 10 cm in size to reduce the risk of recurrence.

Related Links:
City of Hope National Medical Center


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Pediatric Mask
Respire SOFT
New
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.